Tolvaptan, a vasopressin V2 receptor antagonist, is the world’s first approved drug for treatment of autosomal dominant polycystic kidney disease (ADPKD)

Autor:	Yoshihisa Yamada, Hiroyuki Fujiki, Hiroshi Mizuguchi, Yukinobu Takeshita, Katsuji Hattori, Koji Ohmoto, Miki Aihara, Keisuke Nagano, Yoshimasa Isakari, Miho Yamamoto, Yoshitaka Yamamura
Rok vydání:	2022
Předmět:	Pharmacology
Zdroj:	Folia Pharmacologica Japonica. 157:254-260
ISSN:	1347-8397 0015-5691
DOI:	10.1254/fpj.22006
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::181b1af62301b8c4e2d3d00d0265f3f3 https://doi.org/10.1254/fpj.22006 Zobrazit plný text záznamu